

UNC Neonatal-Perinatal Medicine Symposium I

Patent Ductus Arteriosus in premature infants: Clinical trials and equipoise

Suggested Reading

1. Benitz WE. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis? *J Perinatol.* 2010;30(4):241-252.
2. Bixler GM, Powers GC, Clark RH, Walker MW, Tolia VN. Changes in the Diagnosis and Management of Patent Ductus Arteriosus from 2006 to 2015 in United States Neonatal Intensive Care Units. *The Journal of Pediatrics.* 2017;189:105-112.
3. Clyman RI, Liebowitz M. Treatment and Nontreatment of the Patent Ductus Arteriosus: Identifying Their Roles in Neonatal Morbidity. *The Journal of Pediatrics.* 2017;189:13-17.
4. Clyman RI, Liebowitz M, Kaempf J, et al. PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age. *J Pediatr.* 2019;205:41-48.e46.
5. de Waal K, Phad N, Stubbs M, Chen Y, Kluckow M. A Randomized Placebo-Controlled Pilot Trial of Early Targeted Nonsteroidal Anti-Inflammatory Drugs in Preterm Infants with a Patent Ductus Arteriosus. *J Pediatr.* 2021;228:82-86.e82.
6. de Waal K, Prasad R, Kluckow M. Patent ductus arteriosus management and the drift towards therapeutic nihilism - What is the evidence? *Semin Fetal Neonatal Med.* 2021:101219.
7. El-Khuffash A, Bussmann N, Breatnach CR, et al. A Pilot Randomized Controlled Trial of Early Targeted Patent Ductus Arteriosus Treatment Using a Risk Based Severity Score (The PDA RCT). *J Pediatr.* 2021;229:127-133.
8. El-Khuffash A, James AT, Corcoran JD, et al. A Patent Ductus Arteriosus Severity Score Predicts Chronic Lung Disease or Death before Discharge. *J Pediatr.* 2015;167(6):1354-1361.e1352.
9. El-Khuffash A, Weisz DE, McNamara PJ. Reflections of the changes in patent ductus arteriosus management during the last 10 years. *Archives of Disease in Childhood - Fetal and Neonatal Edition.* 2016;101(5):F474.
10. Green CA, Westreich D, Laughon MM, et al. Association of chorioamnionitis and patent ductus arteriosus in a national U.S. cohort. *J Perinatol.* 2021;41(1):119-125. doi:10.1038/s41372-020-00866-x.
11. Gulack BC, Laughon MM, Clark RH, Sankar MN, Hornik CP, Smith PB. Comparative effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus. *Early Hum Dev.* 2015;91(12):725-729. doi:10.1016/j.earlhumdev.2015.08.003.
12. Gupta P. Ibuprofen vs indomethacin for treatment of PDA in preterm infants. *Indian Pediatr.* 1998;35(3):292-293.
13. Gupta S, Juszczak E, Hardy P, et al. Study protocol: baby-OSCAR trial: Outcome after Selective early treatment for Closure of patent ductus arteriosus in preterm babies, a multicentre, masked, randomised placebo-controlled parallel group trial. *BMC Pediatr.* 2021;21(1):100.
14. Jensen EA, Dysart KC, Gantz MG, et al. Association between Use of Prophylactic Indomethacin and the Risk for Bronchopulmonary Dysplasia in Extremely Preterm Infants. *J Pediatr.* 2017;186:34-40.e2. doi:10.1016/j.jpeds.2017.02.003.

15. Lee JH, Greenberg RG, Quek BH, et al. Association between early echocardiography, therapy for patent ductus arteriosus, and outcomes in very low birth weight infants. *Cardiol Young*. 2017;27(9):1732-1739. doi:10.1017/S1047951117001081.
16. Liebowitz M, Kaempf J, Erdeve O, et al. Comparative effectiveness of drugs used to constrict the patent ductus arteriosus: a secondary analysis of the PDA-TOLERATE trial (NCT01958320). *J Perinatol*. 2019;39(5):599-607.
17. Liebowitz M, Katheria A, Sauberan J, et al. Lack of Equipoise in the PDA-TOLERATE Trial: A Comparison of Eligible Infants Enrolled in the Trial and Those Treated Outside the Trial. *J Pediatr*. 2019;213:222-226.e222.
18. Patra A, Thakkar PS, Makhoul M, Bada HS. Objective Assessment of Physiologic Alterations Associated With Hemodynamically Significant Patent Ductus Arteriosus in Extremely Premature Neonates. *Front Pediatr*. 2021;9:648584.
19. Perez KM, Laughon MM. What is new for patent ductus arteriosus management in premature infants in 2015?. *Curr Opin Pediatr*. 2015;27(2):158-164. doi:10.1097/MOP.000000000000200.
20. Puia-Dumitrescu M, Smith PB, Zhao J, et al. Dosing and Safety of Off-label Use of Caffeine Citrate in Premature Infants. *J Pediatr*. 2019;211:27-32.e1. doi:10.1016/j.jpeds.2019.04.028.
21. Reese J, Laughon MM. The Patent Ductus Arteriosus Problem: Infants Who Still Need Treatment. *J Pediatr*. 2015;167(5):954-956. doi:10.1016/j.jpeds.2015.08.023.
22. Resende MH, More K, Nicholls D, Ting J, Jain A, McNamara PJ. The impact of a dedicated patent ductus arteriosus ligation team on neonatal health-care outcomes. *J Perinatol*. 2016;36(6):463-468.
23. Schindler T, Smyth J, Bolisetty S, Michalowski J, Lui K. Early PARacetamol (EPAR) trial: a study protocol for a randomised controlled trial of early paracetamol to promote closure of the ductus arteriosus in preterm infants. *BMJ Open*. 2019;9(10):e031428.
24. Shepherd JL, Noori S. What is a hemodynamically significant PDA in preterm infants? *Congenital Heart Disease*. 2019;14(1):21-26.
25. Smith A, McNamara PJ, El-Khuffash AF. Non-pharmacological management of a hemodynamically significant patent ductus arteriosus. *Semin Fetal Neonatal Med*. 2018;23(4):245-249.
26. Sung SI, Chang YS, Kim J, Choi JH, Ahn SY, Park WS. Natural evolution of ductus arteriosus with noninterventional conservative management in extremely preterm infants born at 23-28 weeks of gestation. *PLoS One*. 2019;14(2):e0212256.
27. Terrin G, Conte F, Oncel MY, et al. Paracetamol for the treatment of patent ductus arteriosus in preterm neonates: a systematic review and meta-analysis. *Archives of Disease in Childhood - Fetal and Neonatal Edition*. 2016;101(2):F127.
28. Thompson EJ, Greenberg RG, Kumar K, et al. Association between Furosemide Exposure and Patent Ductus Arteriosus in Hospitalized Infants of Very Low Birth Weight. *J Pediatr*. 2018;199:231-236. doi:10.1016/j.jpeds.2018.03.067.
29. Ting JY, Resende M, More K, et al. Predictors of respiratory instability in neonates undergoing patent ductus arteriosus ligation after the introduction of targeted milrinone treatment. *J Thorac Cardiovasc Surg*. 2016;152(2):498-504.
30. van Laere D, van Overmeire B, Gupta S, et al. Application of NPE in the assessment of a patent ductus arteriosus. *Pediatr Res*. 2018;84(Suppl 1):46-56.